EDP Sciences logo
Submit your paper
Search
Menu
Home All issues Volume 22 / No 1 (janvier 2016) Med Buccale Chir Buccale, 22 1 (2016) 43-48 References
Open Access
Issue
Med Buccale Chir Buccale
Volume 22, Number 1, janvier 2016
Page(s) 43 - 48
Section Cas clinique et revue de la littérature / Up-to date review and case report
DOI https://doi.org/10.1051/mbcb/2015053
Published online 11 January 2016
  1. Boyce A, Tosi LL, Paul SM. Bisphosphonate treatment for children with disabling conditions. PM R 2014;6:427-436. [CrossRef] [PubMed] [Google Scholar]
  2. Batch JA, Couper JJ, Rodda C, Cowell CT, Zacharin M. Use of bisphosphonate therapy for osteoporosis in childhood and adolescence. J Paediatr Child Health 2003;39:88-92. [CrossRef] [PubMed] [Google Scholar]
  3. Gensburger D, Chapurlat RD Dysplasie fibreuse des os. EMC Appareil locomoteur 2012;7:1-10 article 14-023-F-10. [CrossRef] [Google Scholar]
  4. Chapurlat RD, Orcel P. Fibrous dysplasia of bone and McCune-Albright syndrome. Best Pract Res Clin Rheumatol 2008;22:55-69. [CrossRef] [PubMed] [Google Scholar]
  5. Plotkin H, Rauch F, Zeitlin L, Munns C, Travers R, Glorieux FH. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. J Clin Endocrinol Metab 2003;88:4569-4575. [CrossRef] [PubMed] [Google Scholar]
  6. Liens D, Delmas PD, Meunier PJ. Long-term effects of intraveinous pamidronate in fibrous dysplasia of bone. Lancet 1994;343:953-954. [CrossRef] [PubMed] [Google Scholar]
  7. Cremers SCLM, Pillai G, Papapoulos SE. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 2005; 44:551-570. [CrossRef] [PubMed] [Google Scholar]
  8. Papapoulos SE, Cremers SCLM. Prolonged biphosphonate release after treatment in children. N Engl J Med 2007;356:1075-1076. [CrossRef] [Google Scholar]
  9. Bhatt RA, Hibbert SA, Munns CF. The use of bisphosphonate in children: review of the literature and guidelines for dental management. Australian Dental J 2014;59: 9-19. [CrossRef] [Google Scholar]
  10. Recommandations Société française de stomatologie et de chirurgie maxillofaciale et chirurgie orale. Ostéonécrose des mâchoires en chirurgie oromaxillofaciale et traitements médicamenteux à risque (antirésorpteurs osseux, antiangiogéniques). Juillet 2013. http://www.sfscmfco.fr/ [Google Scholar]
  11. Malmgren B, Aström E, Söderhäll S. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with BP. J Oral Pathol Med 2008;37:196-200. [CrossRef] [PubMed] [Google Scholar]
  12. Schwartz S, Joseph C, Iera D, Vu D-D. Bisphosphonates, Osteonecrosis, Osteogenesis Imperfecta Avulsions: A Case Series. J Can Dent Assoc 2008;74:537-542. [Google Scholar]
  13. Phillipi CA, Remmington T, Steiner RD. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 2008; 8:CD005088. [Google Scholar]
  14. Ward L, Tricco A, Phuong P, Cranney A, Barrowman N, Gaboury I, et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev 2007;4: CD005324. [PubMed] [Google Scholar]
  15. Hoff AO, Toth BB, Altundag K, Jonhson MM, Warneke CL, Hu M., et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous biphosphonates. J Bone Miner Res 2008;23:826-836. [CrossRef] [PubMed] [Google Scholar]
  16. Hillner B, Ingle J, Chlebowski R, Gralow J, Yee GC, Janjan NA, et al. American Society of Clinical Oncology 2003 update on the role of biphosphonates and health issues with cancer. J Clin Oncol 2003;21:4042-4057. Erratum in: J Clin Oncol 2004;22: 1351. [CrossRef] [PubMed] [Google Scholar]
  17. Rattin C, Vanoli A, Latombe I. Ostéonécrose extensive des maxillaires induite par les biphosphonates. Ann Otolaryngol Chir Cervicofac 2008;125:24-29. [CrossRef] [PubMed] [Google Scholar]
  18. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of biphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19:733-759. [CrossRef] [PubMed] [Google Scholar]
  19. Cremers S, Papapoulos S. Pharmacology of bisphosphonates. Review. Bone. 2011;49:42-49. [CrossRef] [Google Scholar]
  20. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis in the jaw in cancer after treatment with biphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-8587. [CrossRef] [PubMed] [Google Scholar]
  21. Iglesias-Linares A, Yáñez-Vico RM, Solano-Reina E, Torres-Lagares D, González Moles MA. Influence of bisphosphonates in orthodontic therapy: Systematic review. J Dent 2010;38:603-611. [CrossRef] [PubMed] [Google Scholar]
  22. Zahrowski JJ. Bisphosphonate treatment: an orthodontic concern calling for a proactive approach. Am J Orthod Dentofacial Orthop 2007;131:311-320. [CrossRef] [PubMed] [Google Scholar]
  23. Graham JW. Bisphosphonates and orthodontics: clinical implications. J Clin Orthod 2006;40:425-428. [PubMed] [Google Scholar]
  24. Krieger E, Jacobs C, Walter C, Wehrbein H. Current state of orthodontic patients under bisphosphonate therapy. Head Face Med 2013;4:9-10. [Google Scholar]
  25. Akintoye SO, Boyce AM, Collins MT. Dental perspectives in fibrous dysplasia and McCune-Albright syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol 2013;116:49-55. [CrossRef] [PubMed] [Google Scholar]
  26. Kamoun-Goldrat A, Ginisty D, Le Merrer M. Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta. Eur J Oral Sci 2008;116:195-198. [CrossRef] [PubMed] [Google Scholar]
  27. Hiraga T, Ninomiya T, Hosoya A, Nakamura H. Administration of the bisphosphonate zoledronic acid during tooth development inhibits tooth eruption and formation and induces dental abnormalities in rats. Calcif Tissue Int 2010;86:502-510. [CrossRef] [PubMed] [Google Scholar]
  28. Lézot F, Chesneau J, Battaglia S, Brion R, Castaneda B, Farges JC. Preclinical evidence of potential craniofacial adverse effect of zoledronic acid in pediatric patients with bone malignancies. Bone 2014;68:146-152. [CrossRef] [PubMed] [Google Scholar]
  29. Chapurlat RD, Hugueny P, Delmas PD, Meunier PJ. Treatment of fibrous dysplasia of bone, with intravenous pamidronate: long-term effectiveness ans evaluation of predictors of response to treatment. Bone 2004;35:235-242. [CrossRef] [PubMed] [Google Scholar]
  30. Isaia GC, Lala R, Defilippi C, Matarazzo P, Andreo M, Roggia C, et al. Bone turnover in children and adolescents with McCune-Albright syndrome treated with pamidronate for bone fibrous dysplasia. Calcif Tissue Int 2002;71:121-128. [CrossRef] [PubMed] [Google Scholar]
  31. Schwartz S, Joseph C, Iera D, Vu DD. Bisphosphonates, osteonecrosis, osteogenesis imperfecta and dental extractions: a case series. J Can Dent Assoc 2008;74:537-542. [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.